May 23, 2014
Roxane Laboratories Inc. scored a victory Wednesday when a New Jersey federal judge invalidated Prometheus Laboratories Inc.'s patent on a treatment for irritable bowel syndrome, ending Prometheus' case accusing Roxane of infringement by planning to produce a generic version of the treatment.